Career history of Alfredo Zurlo
Former positions of Alfredo Zurlo
| Companies | Position | Start | End |
|---|---|---|---|
| MOLOGEN AG | Chief Tech/Sci/R&D Officer | 2013-03-31 | 2016-03-30 |
| SCANDION ONCOLOGY A/S | Chief Tech/Sci/R&D Officer | 2022-05-10 | - |
Glycotope GmbH
 Glycotope GmbH BiotechnologyHealth Technology Glycotope GmbH operates as a biotechnology company to develop pharmaceutical therapeutics and nutrition additives. It focuses on the optimization and humanization of therapeutically relevant sugar structures on biopharmaceuticals known as glycosylation and on the development of innovative antibodies targeting glycostructures on cell surfaces. The company was founded by Steffen Goletz and Andreas Eckert in Febraury 2001 and is headquartered in Berlin, Germany. | Chief Executive Officer | 2016-04-30 | - |
Training of Alfredo Zurlo
| The American University of Rome | Doctorate Degree |
Statistics
International
| Germany | 3 |
| Italy | 2 |
| Denmark | 2 |
Operational
| Chief Tech/Sci/R&D Officer | 2 |
| Doctorate Degree | 1 |
| Chief Executive Officer | 1 |
Sectoral
| Health Technology | 3 |
| Commercial Services | 2 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| MOLOGEN AG | Commercial Services |
| SCANDION ONCOLOGY A/S | Health Technology |
| Private companies | 1 |
|---|---|
Glycotope GmbH
Glycotope GmbH BiotechnologyHealth Technology Glycotope GmbH operates as a biotechnology company to develop pharmaceutical therapeutics and nutrition additives. It focuses on the optimization and humanization of therapeutically relevant sugar structures on biopharmaceuticals known as glycosylation and on the development of innovative antibodies targeting glycostructures on cell surfaces. The company was founded by Steffen Goletz and Andreas Eckert in Febraury 2001 and is headquartered in Berlin, Germany. | Health Technology |
- Stock Market
- Insiders
- Alfredo Zurlo
- Experience
